Skip to main content
Erschienen in: Annals of Hematology 2/2019

29.10.2018 | Original Article

Autoimmune disease-associated non-Hodgkin’s lymphoma—a large retrospective study from China

verfasst von: Shaoxuan Hu, Daobin Zhou, Yongji Wu, Yongqiang Zhao, Shujie Wang, Bing Han, Minghui Duan, Jian Li, Tienan Zhu, Junling Zhuang, Xinxin Cao, Huacong Cai, Jun Feng, Yan Zhang, Fengchun Zhang, Xiaofeng Zeng, Yan Zhao, Qian Wang, Wei Zhang

Erschienen in: Annals of Hematology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

The incidence and clinical implications of autoimmune diseases (ADs) in patients with non-Hodgkin’s lymphoma(NHL) remain unclear. The aim of this study was to examine the prevalence of ADs in NHL and define the clinical characteristics and prognosis of AD-associated NHL patients. Patients diagnosed with NHL in our institute between 1995 and 2017 were retrospectively reviewed to assess the incidence of ADs. Of 4880 patients with NHL, 140 (2.9%) presented with autoimmunity, with a total of 24 ADs. The most common AD was Sjögren syndrome, followed by autoimmune cytopenia, psoriasis, rheumatoid arthritis, etc. Psoriasis and rheumatoid arthritis were significantly associated with pre-existing ADs, whereas autoimmune cytopenia was significantly associated with secondary AD. Sjögren syndrome was significantly associated with B-cell lymphoma, and systemic vasculitis was significantly associated with T-cell lymphoma. Patients with AD-associated NHL had a high frequency of extranodal involvement(87%), with significant associations between specific extranodal sites of lymphoma and subtypes of ADs. Among patients with available data on pre-treatment peripheral blood Epstein-Barr virus (EBV) DNA(n = 68), elevated EBV-DNA load was observed in a variety of NHL subtypes, including 20% of marginal zone lymphoma and 14.3% of follicular lymphoma patients. In a matched-pair analysis, survival did not differ significantly between NHL patients with and without ADs. However, for NHL patients with pre-existing ADs, a prior history of systemic corticosteroids therapy was significantly associated with worse survival (HR = 7.33, P = 0.006). Taken together, our data suggest that a broad spectrum of ADs is associated with NHL, and AD-associated NHL has distinct features with regard to clinical manifestations and prognosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL et al (2012) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef Torre LA, Bray F, Siegel RL et al (2012) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef
2.
Zurück zum Zitat Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132CrossRef Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132CrossRef
3.
Zurück zum Zitat Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundström C, Åkerman M, Melbye M, Glimelius B, Adami HO (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98:51–60CrossRefPubMed Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundström C, Åkerman M, Melbye M, Glimelius B, Adami HO (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98:51–60CrossRefPubMed
4.
Zurück zum Zitat Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, la Vecchia C, Zheng T, Becker N, de Sanjose S, Chiu BCH, Dal Maso L, Cocco P, Maynadie M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph consortium. Blood 111:4029–4038CrossRefPubMedPubMedCentral Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, la Vecchia C, Zheng T, Becker N, de Sanjose S, Chiu BCH, Dal Maso L, Cocco P, Maynadie M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph consortium. Blood 111:4029–4038CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K (2014) Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol 25:2025–2030CrossRefPubMed Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K (2014) Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol 25:2025–2030CrossRefPubMed
6.
Zurück zum Zitat Hauswirth AW, Skrabs C, Schützinger C, Gaiger A, Lechner K, Jäger U (2007) Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leuk Lymphoma 48:1139–1149CrossRefPubMed Hauswirth AW, Skrabs C, Schützinger C, Gaiger A, Lechner K, Jäger U (2007) Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leuk Lymphoma 48:1139–1149CrossRefPubMed
7.
8.
Zurück zum Zitat Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R (2014) Lymphoma development in patients with autoimmune and inflammatory disorders—what are the driving forces? Semin Cancer Biol 24:61–70CrossRefPubMed Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R (2014) Lymphoma development in patients with autoimmune and inflammatory disorders—what are the driving forces? Semin Cancer Biol 24:61–70CrossRefPubMed
9.
Zurück zum Zitat Hoshida Y, Xu JX, Fujita S et al (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322–331PubMed Hoshida Y, Xu JX, Fujita S et al (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322–331PubMed
10.
Zurück zum Zitat Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR (2015) Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 13:847–858CrossRefPubMed Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR (2015) Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 13:847–858CrossRefPubMed
11.
Zurück zum Zitat Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yoshida M, Ishibashi Y, Nakashima S, Sugita Y, Miura O, Ohshima K (2013) Methotrexate iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein–Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91:20–28CrossRefPubMed Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yoshida M, Ishibashi Y, Nakashima S, Sugita Y, Miura O, Ohshima K (2013) Methotrexate iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein–Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91:20–28CrossRefPubMed
12.
Zurück zum Zitat Vos AC, Bakkal N, Minnee RC et al (2011) Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 17:1837–1845CrossRefPubMed Vos AC, Bakkal N, Minnee RC et al (2011) Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 17:1837–1845CrossRefPubMed
13.
Zurück zum Zitat Martin DN, Mikhail IS, Landgren O (2009) Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 50:541–550CrossRefPubMed Martin DN, Mikhail IS, Landgren O (2009) Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 50:541–550CrossRefPubMed
14.
Zurück zum Zitat Duhrsen U, Augener W, Zwingers T, Brittinger G (1987) Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 67:235–239CrossRefPubMed Duhrsen U, Augener W, Zwingers T, Brittinger G (1987) Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 67:235–239CrossRefPubMed
15.
Zurück zum Zitat Váróczy L, Gergely L, Zeher M et al (2002) Malignant lymphoma-associated autoimmune diseases—a descriptive epidemiological study. Rheumatol Int 22:233–237CrossRefPubMed Váróczy L, Gergely L, Zeher M et al (2002) Malignant lymphoma-associated autoimmune diseases—a descriptive epidemiological study. Rheumatol Int 22:233–237CrossRefPubMed
16.
Zurück zum Zitat Váróczy L, Páyer E, Kádár Z, Gergely L, Miltényi Z, Magyari F, Szodoray P, Illés Á (2012) Malignant lymphomas and autoimmunity—a single center experience from Hungary. Clin Rheumatol 31:219–224CrossRefPubMed Váróczy L, Páyer E, Kádár Z, Gergely L, Miltényi Z, Magyari F, Szodoray P, Illés Á (2012) Malignant lymphomas and autoimmunity—a single center experience from Hungary. Clin Rheumatol 31:219–224CrossRefPubMed
17.
Zurück zum Zitat Jachiet V, Mekinian A, Carrat F, Grignano E, Retbi A, Boffa JJ, Ronco P, Rondeau E, Sellam J, Berenbaum F, Chazouillères O, Capron J, Alamowitch S, Chasset F, Frances C, Coppo P, Fain O, on behalf of French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON) (2017) Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leuk Lymphoma 59:1399–1405. https://doi.org/10.1080/10428194.2017.1379075 CrossRefPubMed Jachiet V, Mekinian A, Carrat F, Grignano E, Retbi A, Boffa JJ, Ronco P, Rondeau E, Sellam J, Berenbaum F, Chazouillères O, Capron J, Alamowitch S, Chasset F, Frances C, Coppo P, Fain O, on behalf of French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON) (2017) Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leuk Lymphoma 59:1399–1405. https://​doi.​org/​10.​1080/​10428194.​2017.​1379075 CrossRefPubMed
18.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H (eds) World Health Organization classification of Tumours. IARC, Lyon, p 439 Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H (eds) World Health Organization classification of Tumours. IARC, Lyon, p 439
19.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRef
20.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588CrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588CrossRef
21.
Zurück zum Zitat Koff JL, Rai A, Flowers CR (2018) Characterizing autoimmune disease-associated diffuse large B-cell lymphoma in a SEER-Medicare cohort. Clin Lymphoma Myeloma Leuk 18:e115–e121CrossRefPubMed Koff JL, Rai A, Flowers CR (2018) Characterizing autoimmune disease-associated diffuse large B-cell lymphoma in a SEER-Medicare cohort. Clin Lymphoma Myeloma Leuk 18:e115–e121CrossRefPubMed
22.
Zurück zum Zitat Johnsen SJ, Brun JG, Gøransson LG, Småstuen MC, Johannesen TB, Haldorsen K, Harboe E, Jonsson R, Meyer PA, Omdal R (2013) Risk of non-Hodgkin’s lymphoma in primary Sjögren’s syndrome: a population-based study. Arthritis Care Res (Hoboken) 65:816–821CrossRef Johnsen SJ, Brun JG, Gøransson LG, Småstuen MC, Johannesen TB, Haldorsen K, Harboe E, Jonsson R, Meyer PA, Omdal R (2013) Risk of non-Hodgkin’s lymphoma in primary Sjögren’s syndrome: a population-based study. Arthritis Care Res (Hoboken) 65:816–821CrossRef
23.
Zurück zum Zitat Liang Y, Yang Z, Qin B, Zhong R (2014) Primary Sjogren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73:1151–1156CrossRefPubMed Liang Y, Yang Z, Qin B, Zhong R (2014) Primary Sjogren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73:1151–1156CrossRefPubMed
24.
Zurück zum Zitat Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, Canninga-van Dijk MR, Carlotti A, Geerts ML, Hahtola S, Hummel M, Jeskanen L, Kempf W, Massone C, Ortiz-Romero PL, Paulli M, Petrella T, Ranki A, Peralto JLR, Robson A, Senff NJ, Vermeer MH, Wechsler J, Whittaker S, Meijer CJLM (2008) Subcutaneous panniculitis-like T-cell lymphoma: definition, classification and prognostic factors. An EORTC cutaneous lymphoma group study of 83 cases. Blood 111:838–845CrossRefPubMed Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, Canninga-van Dijk MR, Carlotti A, Geerts ML, Hahtola S, Hummel M, Jeskanen L, Kempf W, Massone C, Ortiz-Romero PL, Paulli M, Petrella T, Ranki A, Peralto JLR, Robson A, Senff NJ, Vermeer MH, Wechsler J, Whittaker S, Meijer CJLM (2008) Subcutaneous panniculitis-like T-cell lymphoma: definition, classification and prognostic factors. An EORTC cutaneous lymphoma group study of 83 cases. Blood 111:838–845CrossRefPubMed
25.
Zurück zum Zitat Tisi MC, Cupelli E, Santangelo R, Maiolo E, Alma E, Giachelia M, Martini M, Bellesi S, D’Alò F, Voso MT, Pompili M, Leone G, Larocca LM, Hohaus S (2016) Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leuk Lymphoma 57:628–634CrossRefPubMed Tisi MC, Cupelli E, Santangelo R, Maiolo E, Alma E, Giachelia M, Martini M, Bellesi S, D’Alò F, Voso MT, Pompili M, Leone G, Larocca LM, Hohaus S (2016) Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leuk Lymphoma 57:628–634CrossRefPubMed
26.
Zurück zum Zitat Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, Fukushima N, Isobe Y, Takizawa J, Hasegawa Y, Kobayashi H, Okamura S, Kobayashi H, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Kawa K, Oshimi K, Suzuki R (2012) Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res 18:4183–4190CrossRefPubMed Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, Fukushima N, Isobe Y, Takizawa J, Hasegawa Y, Kobayashi H, Okamura S, Kobayashi H, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Kawa K, Oshimi K, Suzuki R (2012) Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res 18:4183–4190CrossRefPubMed
27.
Zurück zum Zitat Kim YR, Kim SJ, Cheong JW et al (2017) Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. Oncotarget 8:92312–92323PubMedPubMedCentral Kim YR, Kim SJ, Cheong JW et al (2017) Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. Oncotarget 8:92312–92323PubMedPubMedCentral
28.
Zurück zum Zitat Grywalska E, Rolinski J (2015) Epstein-Barr virus-associated lymphomas. Semin Oncol 42:291–303CrossRefPubMed Grywalska E, Rolinski J (2015) Epstein-Barr virus-associated lymphomas. Semin Oncol 42:291–303CrossRefPubMed
29.
Zurück zum Zitat Shih YH, Yang Y, Chang KH, Chen YH, Teng CLJ (2018) Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. Int J Rheum Dis 21:93–101CrossRefPubMed Shih YH, Yang Y, Chang KH, Chen YH, Teng CLJ (2018) Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. Int J Rheum Dis 21:93–101CrossRefPubMed
30.
Zurück zum Zitat Xing K, Gu B, Zhang P, Wu X (2015) Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunol 16:39CrossRefPubMedPubMedCentral Xing K, Gu B, Zhang P, Wu X (2015) Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunol 16:39CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11(Suppl 1):S45–S55CrossRefPubMed Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11(Suppl 1):S45–S55CrossRefPubMed
Metadaten
Titel
Autoimmune disease-associated non-Hodgkin’s lymphoma—a large retrospective study from China
verfasst von
Shaoxuan Hu
Daobin Zhou
Yongji Wu
Yongqiang Zhao
Shujie Wang
Bing Han
Minghui Duan
Jian Li
Tienan Zhu
Junling Zhuang
Xinxin Cao
Huacong Cai
Jun Feng
Yan Zhang
Fengchun Zhang
Xiaofeng Zeng
Yan Zhao
Qian Wang
Wei Zhang
Publikationsdatum
29.10.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 2/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3515-2

Weitere Artikel der Ausgabe 2/2019

Annals of Hematology 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.